BPMC - FDA lifts partial clinical hold on Blueprint Medicine cancer candidate BLU-222

2023-03-28 17:48:21 ET

• The US FDA has lifted a partial clinical hold placed in February on Blueprint Medicines' ( NASDAQ: BPMC ) early stage candidate BLU-222 for CDK2-vulnerable cancers.
• The hold was due to visual adverse events, such as short lasting, reversible episodes of light sensitivity and blurred vision seen in a few patients.
• Blueprint ( BPMC ) plans on presenting initial dose escalation data from the phase 1/2 VELA trial in Q2.
• Company shares are up 3.5% in after-hours trading.
• Read why Seeking Alpha contributor Stephen Ayers just initiated a buy rating on Blueprint ( BPMC ).

For further details see: